Jardiance patents in canada?

Short answer: Jardiance (empagliflozin) in Canada is protected by Canadian patent filings, including at least a composition‑of‑matter patent for the compound and related patents on uses, formulations, and possibly synthesis/formulations. The exact CA patent numbers and their expiry dates require checking Canadian patent databases (CIPO) and patent family members (e.g., Espacenet, WIPO Patentscope).

What I can do for you
- Provide a current summary of the Canadian patent landscape for empagliflozin (Jardiance), including:
- Canadian patent family members covering empagliflozin itself (composition of matter)
- Use patents (e.g., treatment of type 2 diabetes, cardiovascular risk reduction)
- Formulation, process, or crystalline form patents
- Give you the patent numbers (CA publications), status (granted/pending), and expiry dates, plus notes on whether they’re part of the same family as US/EU grants.
- Outline regulatory exclusivity considerations in Canada (data protection for new chemical entities and any pediatric extensions), which can affect market protection beyond patents.

If you want me to pull the exact CA patent numbers and expiry dates now, I can search CIPO, Espacenet, and WIPO Patentscope and summarize them for you. A couple of quick questions to tailor the lookup:
- Are you after a freedom-to-operate (FTO) view for a generic entrant, or just a general patent landscape?
- Do you want only granted Canadian patents, or also pending CA applications and related family members?

Note: Patent status and expiry dates can be updated over time; for any legal or FTO conclusions, consider consulting a patent attorney.